An observational study in Osteoporosis, Osteoporosis, Steroid Induced and Inflammatory Rheumatism, sponsored by Diakonhjemmet Hospital. Recruiting at 2 sites in Norway. Open to participants aged 25 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-08-19.
Sponsored by Diakonhjemmet Hospital · Observational
Bone turnover markers (BTMs) are recommended as an important tool in follow-up of osteoporosis treatment. However, there is a lack of knowledge in the reliability of BTMs during and after glucocorticoid treatment. Glucocorticoids suppresses BTMs during treatment with at least 30% and, moreover, glucocorticoids increase the risk of fractures. Patients with an inflammatory joint disease are at increased risk of osteoporosis, and disease flares are often treated with glucocorticoids, which in turn can lead to loss in reliability of the BTMs in patients who also are on osteoporosis treatment.
There is a need of more knowledge on BTM changes during and after glucocorticoid treatment for optimized patientcare, reduced risk of side effects and reduced health economic costs.
1,601 studies on the registry are indexed under Osteoporosis; 209 are open to participants now.
This study's planned enrollment of 160 is close to the median of 160 across 455 observational studies indexed under Osteoporosis.
Browse Osteoporosis studies →Diakonhjemmet Hospital is the lead sponsor of 62 studies on the registry; 14 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with a diagnosis of rheumatoid arthritis or spondyloarthritis or psoriatic arthritis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with a new diagnosis of rheumatoid arthritis and indication for initiating DMARD treatment with a bridging of oral glucocorticoid treatment. Women should be premenopausal and men younger than 50 years.
Drug: Glucocorticoid Effect
Patients with a new diagnosis of rheumatoid arthritis and indication for initiating DMARD treatment with a bridging of oral glucocorticoid treatment. Women should be postmenopausal and men older than 50 years.
Drug: Glucocorticoid Effect
Patients with a new diagnosis of spondyloarthritis and indication of DMARD treatment without glucocorticoid treatment. Women should be premenopausal and men younger than 50 years.
Patients with a new diagnosis of psoriatic arthritis and indication of DMARD treatment without glucocorticoid treatment. Women should be premenopausal and men younger than 50 years.
Patients with an inflammatory joint disease on stable DMARD treatment weith indication of intraarticular glucocorticoid injection. Women should be premenopausal and men younger than 50 years.
Drug: Glucocorticoid Effect
Patients with an inflammatory joint disease on stable DMARD treatment weith indication of intramuscular glucocorticoid injection. Women should be premenopausal and men younger than 50 years.
Drug: Glucocorticoid Effect
Patients with or without glucocorticoid treatment will be observed regarding the level of bone turnover markers (P1NP and CTX1) every 4 weeks til 6 months after the last glucocorticoid dose.
P1NP level 3 months after glucocorticoid termination
P1NP in a blood sample
Time frame: september 2024 til december 2025
P1NP level 6 months after glucocorticoid termination
P1NP in a blood sample
Time frame: september 2024 til december 2025
CTX1 level 3 and 6 months after glucocorticoid termination
CTX1 in a blood sample
Time frame: september 2024 til december 2025
P1NP and CTX1 dynamic until 6 months after treatment of inflammation without glucocorticoids
P1NP and CTX1 in a blood sample
Time frame: september 2024 til december 2025
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2025 (actual). Primary completion is estimated for Oct 2027, 33 months after the start.
Of 114 non-industry observational studies under Osteoporosis, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 113. This study's planned 33 months is below that.
Counting every sponsor, half of 125 studies reached it within 51 months; a quarter within 24 and three quarters within 97.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Diakonhjemmet Hospital